Vismodegib

(Erivedge®)

Erivedge®

Drug updated on 4/15/2024

Dosage FormCapsule (oral; 150 mg)
Drug ClassHedgehog pathway inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Vismodegib (Erivedge) is indicated for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery, or for those who are not candidates for surgery and radiation. It demonstrated a pooled overall response rate of 68.5% in treating advanced basal cell carcinoma.
  • The information was derived from two systematic reviews/meta-analyses focusing on Sonic Hedgehog inhibitors, specifically vismodegib (Erivedge) and sonidegib.
  • In terms of the safety profile, adverse effects reported include muscle spasms (70.5%), dysgeusia (58.4%), alopecia (59.9%), and weight loss (35.1%). Weight loss was notably significant among these side effects.
  • Compared to another drug called sonidegib used in similar conditions, vismodegib showed higher efficacy in treating advanced basal cell carcinoma but was less effective compared to sonidegib in SHH-driven medulloblastoma, especially among pediatric patients where sonidegib's efficacy was 3.67-fold higher.
  • The use of both drugs in the treatment of advanced BCC in adults shows varying degrees of effectiveness; however, vismodegib generally proved more effective based on overall response rates.
  • Considering population types and subgroup considerations such as age group-specific cancer subtype like SHH-driven MB, which predominantly affects children but also occurs in adults, sonidegib has shown superior effectiveness over vismodegib particularly amongst pediatric patients while maintaining comparable safety profiles across indications, albeit specific prevalence varied between adverse effects.